Financhill
Sell
25

MRK Quote, Financials, Valuation and Earnings

Last price:
$98.94
Seasonality move :
1.97%
Day range:
$97.90 - $99.68
52-week range:
$94.48 - $134.63
Dividend yield:
3.18%
P/E ratio:
20.56x
P/S ratio:
3.95x
P/B ratio:
5.57x
Volume:
29.2M
Avg. volume:
13.5M
1-year change:
-6.94%
Market cap:
$248B
Revenue:
$60.1B
EPS (TTM):
$4.77

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MRK
Merck &
$16.5B $1.57 5.76% -15.62% $128.73
AMGN
Amgen
$8.5B $5.11 8.07% 255.18% $322.43
JNJ
Johnson & Johnson
$22.2B $2.21 4.95% 21.99% $172.53
LLY
Eli Lilly and
$12.1B $1.47 49.68% 124.93% $984.05
MRNA
Moderna
$1.2B -$1.94 -63.53% -79.68% $127.09
PFE
Pfizer
$14.9B $0.61 27.51% 12.4% $31.86
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MRK
Merck &
$98.05 $128.73 $248B 20.56x $0.81 3.18% 3.95x
AMGN
Amgen
$263.38 $322.43 $141.6B 33.72x $2.25 3.42% 4.37x
JNJ
Johnson & Johnson
$144.47 $172.53 $347.8B 23.88x $1.24 3.36% 4.00x
LLY
Eli Lilly and
$767.76 $984.05 $728.8B 83.00x $1.30 0.68% 16.99x
MRNA
Moderna
$39.39 $127.09 $15.2B -- $0.00 0% 3.01x
PFE
Pfizer
$26.36 $31.86 $149.4B 35.62x $0.42 6.37% 2.52x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MRK
Merck &
46.15% 0.824 13.95% 0.88x
AMGN
Amgen
88.92% -0.086 34.87% 0.80x
JNJ
Johnson & Johnson
33.76% 0.599 9.16% 0.70x
LLY
Eli Lilly and
68.61% 0.948 3.9% 0.63x
MRNA
Moderna
-- 0.826 -- 3.95x
PFE
Pfizer
41.92% 0.516 40.56% 0.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MRK
Merck &
$12.6B $4B 15.67% 29.26% 26.54% $8.5B
AMGN
Amgen
$5.2B $2B 6.14% 65.35% 45.6% $3.3B
JNJ
Johnson & Johnson
$15.5B $5.3B 14.07% 20.88% 15.71% $5.7B
LLY
Eli Lilly and
$9.3B $4.4B 21.5% 66.4% 15.57% -$458.9M
MRNA
Moderna
$1.3B -$70M -17.44% -17.44% 1.46% -$1.7B
PFE
Pfizer
$12.4B $5.3B 2.66% 4.63% 31.06% $6.1B

Merck & vs. Competitors

  • Which has Higher Returns MRK or AMGN?

    Amgen has a net margin of 18.95% compared to Merck &'s net margin of 33.28%. Merck &'s return on equity of 29.26% beat Amgen's return on equity of 65.35%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.51% $1.24 $82.7B
    AMGN
    Amgen
    61.07% $5.22 $67.9B
  • What do Analysts Say About MRK or AMGN?

    Merck & has a consensus price target of $128.73, signalling upside risk potential of 31.29%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 22.42%. Given that Merck & has higher upside potential than Amgen, analysts believe Merck & is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    16 7 0
    AMGN
    Amgen
    10 15 2
  • Is MRK or AMGN More Risky?

    Merck & has a beta of 0.393, which suggesting that the stock is 60.746% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.

  • Which is a Better Dividend Stock MRK or AMGN?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.18%. Amgen offers a yield of 3.42% to investors and pays a quarterly dividend of $2.25 per share. Merck & pays 2039.73% of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Amgen's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

  • Which has Better Financial Ratios MRK or AMGN?

    Merck & quarterly revenues are $16.7B, which are larger than Amgen quarterly revenues of $8.5B. Merck &'s net income of $3.2B is higher than Amgen's net income of $2.8B. Notably, Merck &'s price-to-earnings ratio is 20.56x while Amgen's PE ratio is 33.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.95x versus 4.37x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.95x 20.56x $16.7B $3.2B
    AMGN
    Amgen
    4.37x 33.72x $8.5B $2.8B
  • Which has Higher Returns MRK or JNJ?

    Johnson & Johnson has a net margin of 18.95% compared to Merck &'s net margin of 11.99%. Merck &'s return on equity of 29.26% beat Johnson & Johnson's return on equity of 20.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.51% $1.24 $82.7B
    JNJ
    Johnson & Johnson
    69.01% $1.11 $105.9B
  • What do Analysts Say About MRK or JNJ?

    Merck & has a consensus price target of $128.73, signalling upside risk potential of 31.29%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 20.63%. Given that Merck & has higher upside potential than Johnson & Johnson, analysts believe Merck & is more attractive than Johnson & Johnson.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    16 7 0
    JNJ
    Johnson & Johnson
    8 13 0
  • Is MRK or JNJ More Risky?

    Merck & has a beta of 0.393, which suggesting that the stock is 60.746% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

  • Which is a Better Dividend Stock MRK or JNJ?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.18%. Johnson & Johnson offers a yield of 3.36% to investors and pays a quarterly dividend of $1.24 per share. Merck & pays 2039.73% of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

  • Which has Better Financial Ratios MRK or JNJ?

    Merck & quarterly revenues are $16.7B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Merck &'s net income of $3.2B is higher than Johnson & Johnson's net income of $2.7B. Notably, Merck &'s price-to-earnings ratio is 20.56x while Johnson & Johnson's PE ratio is 23.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.95x versus 4.00x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.95x 20.56x $16.7B $3.2B
    JNJ
    Johnson & Johnson
    4.00x 23.88x $22.5B $2.7B
  • Which has Higher Returns MRK or LLY?

    Eli Lilly and has a net margin of 18.95% compared to Merck &'s net margin of 8.48%. Merck &'s return on equity of 29.26% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.51% $1.24 $82.7B
    LLY
    Eli Lilly and
    81.02% $1.07 $45.4B
  • What do Analysts Say About MRK or LLY?

    Merck & has a consensus price target of $128.73, signalling upside risk potential of 31.29%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 28.17%. Given that Merck & has higher upside potential than Eli Lilly and, analysts believe Merck & is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    16 7 0
    LLY
    Eli Lilly and
    15 6 0
  • Is MRK or LLY More Risky?

    Merck & has a beta of 0.393, which suggesting that the stock is 60.746% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

  • Which is a Better Dividend Stock MRK or LLY?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.18%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.30 per share. Merck & pays 2039.73% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

  • Which has Better Financial Ratios MRK or LLY?

    Merck & quarterly revenues are $16.7B, which are larger than Eli Lilly and quarterly revenues of $11.4B. Merck &'s net income of $3.2B is higher than Eli Lilly and's net income of $970.3M. Notably, Merck &'s price-to-earnings ratio is 20.56x while Eli Lilly and's PE ratio is 83.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.95x versus 16.99x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.95x 20.56x $16.7B $3.2B
    LLY
    Eli Lilly and
    16.99x 83.00x $11.4B $970.3M
  • Which has Higher Returns MRK or MRNA?

    Moderna has a net margin of 18.95% compared to Merck &'s net margin of 0.7%. Merck &'s return on equity of 29.26% beat Moderna's return on equity of -17.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.51% $1.24 $82.7B
    MRNA
    Moderna
    72.29% $0.03 $11.9B
  • What do Analysts Say About MRK or MRNA?

    Merck & has a consensus price target of $128.73, signalling upside risk potential of 31.29%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 88.34%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    16 7 0
    MRNA
    Moderna
    7 12 1
  • Is MRK or MRNA More Risky?

    Merck & has a beta of 0.393, which suggesting that the stock is 60.746% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

  • Which is a Better Dividend Stock MRK or MRNA?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.18%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 2039.73% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MRK or MRNA?

    Merck & quarterly revenues are $16.7B, which are larger than Moderna quarterly revenues of $1.9B. Merck &'s net income of $3.2B is higher than Moderna's net income of $13M. Notably, Merck &'s price-to-earnings ratio is 20.56x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.95x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.95x 20.56x $16.7B $3.2B
    MRNA
    Moderna
    3.01x -- $1.9B $13M
  • Which has Higher Returns MRK or PFE?

    Pfizer has a net margin of 18.95% compared to Merck &'s net margin of 25.23%. Merck &'s return on equity of 29.26% beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    MRK
    Merck &
    75.51% $1.24 $82.7B
    PFE
    Pfizer
    70.27% $0.78 $159.2B
  • What do Analysts Say About MRK or PFE?

    Merck & has a consensus price target of $128.73, signalling upside risk potential of 31.29%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Merck & has higher upside potential than Pfizer, analysts believe Merck & is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    MRK
    Merck &
    16 7 0
    PFE
    Pfizer
    8 13 1
  • Is MRK or PFE More Risky?

    Merck & has a beta of 0.393, which suggesting that the stock is 60.746% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

  • Which is a Better Dividend Stock MRK or PFE?

    Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.18%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Merck & pays 2039.73% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios MRK or PFE?

    Merck & quarterly revenues are $16.7B, which are smaller than Pfizer quarterly revenues of $17.7B. Merck &'s net income of $3.2B is lower than Pfizer's net income of $4.5B. Notably, Merck &'s price-to-earnings ratio is 20.56x while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 3.95x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MRK
    Merck &
    3.95x 20.56x $16.7B $3.2B
    PFE
    Pfizer
    2.52x 35.62x $17.7B $4.5B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 1.96% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 8.6% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 4.43% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock